FDA scientists flag evidence gaps in peptide deregulation push
TL;DR
FDA scientists say seven peptides being considered for compounding pharmacies lack sufficient human data and may pose safety risks, challenging RFK Jr.'s push to deregulate them; an FDA advisory committee will review the evidence July 23–24, but several peptides have little or no human research, raise concerns about contamination and mislabeling, and the FDA must decide, usually following the panel.
- RFK Jr. wants to make it easier to get peptides. FDA scientists disagree. NBC News
- FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr. PBS
- FDA staff question peptides backed by Kennedy ahead of advisory panel review Reuters
- FDA reviewers oppose allowing seven peptides for compounding Endpoints News
- FDA scientists flag concerns with peptides, the trendy molecules RFK Jr. supports NPR
Want the full story? Read the original reporting
Read on NBC News